Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Adenocarcinoma × olaparib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 46 Breast Neoplasms 39 Triple Negative Breast Neoplasms 19 Prostatic Neoplasms 18 Neoplasms 13 Fallopian Tube Neoplasms 13 Endometrial Neoplasms 12 Pancreatic Neoplasms 9 Recurrence 8 Neoplasm Metastasis 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Lung Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Glioma 5 Glioblastoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Carcinoma, Squamous Cell 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Stomach Neoplasms 3 Solid Tumor 3 Melanoma 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2

Interventions

Oxaliplatin 32 Fluorouracil 24 Gemcitabine 23 Leucovorin 19 Docetaxel 19 pembrolizumab 17 Capecitabine 15 Radiotherapy 14 Irinotecan 13 Cisplatin 11 Bevacizumab 11 Nivolumab 8 130-nm albumin-bound paclitaxel 8 Trastuzumab 7 Erlotinib Hydrochloride 7 Cyclophosphamide 7 Albumin-Bound Paclitaxel 7 Radiosurgery 6 Paclitaxel 6 Taxes 5 S 1 (combination) 5 Metformin 5 Carboplatin 5 Blood Specimen Collection 5 Sunitinib 4 Sorafenib 4 Pemetrexed 4 Esophagectomy 4 Chemoradiotherapy 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01682772 2019-08-15

TOPARP

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡